Stephen C. Bain

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark et al. · New England Journal of Medicine · 2019 · 1.8K citations · Full text

A genome-wide search for human type 1 diabetes susceptibility genes

June Davies, Yoshihiko Kawaguchi, Simon T. Bennett et al. · Nature · 1994 · 1.3K citations

Genome-wide Association Study, Genetic Determinant, Genetics +6

Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy

Anthony Barnett, Stephen C. Bain, Paul Bouter et al. · New England Journal of Medicine · 2004 · 914 citations · Full text

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Carel W. le Roux, Arne Astrup, Ken Fujioka et al. · The Lancet · 2017 · 813 citations

Obesity, Metabolic Syndrome, Nutrition +8